Benlysta (belimumab) - GSK
Lupkynis (voclosporin) - Aurinia Pharma
Gazyva (obinutuzumab) - Roche, Biogen
Childhood-onset lupus nephritis: unique aspects and challenges in management. (PubMed, Kidney Int) - Aug 23, 2025 - "Novel treatments have become available for adults in the last decade, notably belimumab, obinutuzumab and voclosporin. In this mini review, we will highlight several unique aspects in managing childhood-onset LN (cLN), including the optimal definition of disease remission, prevention of relapse, the delicate balance between treatment efficacy and side-effects, and monogenic forms of lupus nephritis. We will also discuss how treatment adherence and dedicated transition care can affect treatment outcomes." 
Journal • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pediatrics • Renal Disease • Systemic Lupus Erythematosus
http://www.ncbi.nlm.nih.gov/pubmed/40846176
 
Eugene Yu-Hin Chan; Stephen D Marks
 
Aug 23, 2025
 
Prev Next